Study design (if review, criteria of inclusion for studies)
Double-blind, placebo-controlled, randomised cross-over trial. 1 year duration (2 periods of 6 months each).
Participants
19 (13 males; 6 girls) children with CF and liver dysfunction, aged 7 - 17 years (mean (SD) 11. 9 (0. 6) years). 6 withdrawals (1 died, 4 moved away, 1 discontinued medication).
Interventions
UDCA (15 mg/kg/day) versus placebo.
Outcome measures
Liver function tests (AST, ALT, GGT), plasma lipid levels (total fatty acids, triglycerides, cholesterol), plasma RBP, transthyretin, retinol, retinyl ester levels.
Main results
At entry, all patients had biochemical evidence of EFA deficiency. The lipid profiles during an average period of 25 months of follow-up showed a significant decrease in triglycerides (p <0.002), cholesterol (p <0.02), and total fatty acids (p <0.006). In addition, UDCA therapy led to an improvement in EFA status, as indicated by an increase (p <0.05) in the n-6 fatty acid concentration and a reduction (p <0.04) in the 20:3n-9/20:4n-6 fatty acid ratio. Although no change in vitamin E levels was observed, retinol metabolism was altered. There was an increase (p <0.02) in the unesterified retinol/retinol binding protein molar ratio in the absence of a difference in retinol binding protein concentration. Furthermore, retinyl esters, which normally account for less than 3% of circulating retinol, decreased (p <0.05) from 13.7% +/- 3.6% to 8.1% +/- 1.7%.
Authors' conclusions
This study confirms that UDCA alters lipoprotein metabolism and shows that it improves the EFA and retinol status of patients with CF and liver disease.